Alere sticks to its guns as investors gripe; Rexam eyes $1.2B medical unit sale;

 @FierceMedDev: Boston Scientific buying Bard's electrophysiology biz for $275M. News | Follow @FierceMedDev

 @DamianFierce: For CROs big and small, you're only as good as your reputation. The view from DIA 2013: Feature | Follow @DamianFierce

 @MichaelGFierce: SEC hammers imaging company, CEO with fraud charges. Story | Follow @MichaelGFierce

> Despite mounting pressure from investors to restructure, Alere ($ALR) is sticking to its guns, filing proxy materials and reaffirming its board nominations. More

> After being held hostage for almost a week by workers at his company's Chinese plant, Specialty Medical Supplies executive Chip Starnes has paid a ransom and returned home. Story

> Zoll Medical's GPS-like CPR technology helped paramedics nearly double survival rates from out-of-hospital cardiac arrest. News

> Rexam is looking to sell off its healthcare business, which makes inhalers and other medical devices, for up to $1.2 billion. Article

> French diagnostics outfit bioMérieux won a CE mark for its third-generation immunoassay platform. Item

Biotech News

 @FierceBiotech: ICYMI yesterday: J&J's pharma chairman lands 'more deals' in Boston innovation push. News | Follow @FierceBiotech

 @JohnCFierce: Where are the FDA approvals on biosims? EMA backs two Remicade knockoffs. Release | Follow @JohnCFierce

 @RyanMFierce: Big week for Prosensa. Priced $78M IPO on the heels of breakthrough status for lead DMD Rx partnered w/ GSK. PR | More | Follow @RyanMFierce

> Lab animal wars: Scientists blast living conditions of stolen mouse models. Story

> Buyout buzz: Royalty might mount joint effort to acquire Elan. Article

> Resverlogix stock craters on failure of cardio drug trial. Report

Pharma News

 @FiercePharma: Finally… EMA's press release about this week's drug moves: Release | Follow @FiercePharma

 @EricPFierce: There is a connection between the separate deals Aspen has announced with MSD and GSK. It is heparin. More | Follow @EricPFierce

 @CarlyHFierce: There are billions of dollars to be saved on healthcare spending via adherence... but how? Story | Follow @CarlyHFierce

> FDA sends J&J CRL on Xarelto for stent thrombosis. Article

> Dendreon's Provenge gets recommendation in Europe. More

> Pfizer returns to buyback strategy to appease shareholders. Report

Suggested Articles

Dexcom received a new European approval for its wearable continuous glucose monitor in pregnant women across Type 1, Type 2 and gestational diabetes.

Infectious disease blood tester Karius has raised $165 million led by SoftBank’s Vision Fund 2, the Japanese conglomerate’s sequel to its VC megafund.

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.